Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799020 | 1.00 | SLC6A4 (0.58) | SLC6A4CHRM3CYP2D6CYP2C9HIF1A | |
| SCHEMBL28744419 | 0.87 | CYP2D6 (0.73) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL30577950 | 0.86 | CYP2D6 (0.72) | CYP2D6CYP2C9HIF1AOPRK1 | |
| SCHEMBL1370757 | 0.86 | CYP2D6 (0.72) | CYP2D6CYP2C9HIF1AOPRK1 | |
| SCHEMBL7692768 | 0.86 | CYP2D6 (0.68) | CYP2D6CYP2C9HIF1AOPRK1 | |
| SCHEMBL7037977 | 0.85 | CHRM3 (0.69) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL12438436 | 0.85 | CYP2D6 (0.71) | CHRM3CYP2D6CYP2C9HIF1ASIGMAR1 | |
| SCHEMBL1397213 | 0.85 | CYP2D6 (0.75) | CYP2D6CYP2C9HIF1AOPRK1 | |
| SCHEMBL4095012 | 0.83 | CHRM3 (0.81) | CHRM3 | |
| SCHEMBL30577945 | 0.82 | MEN1 (0.57) | CYP2D6CYP2C9HIF1AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | CHEK2, CHEK1, SIK2 | SLC6A4 4773/4885CHRM3 1651/4885CYP2D6 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.